The impact of cannabidiol on the quality of life of patients with epilepsy and chronic pain
The impact of cannabidiol on the quality of life of patients with epilepsy and chronic pain
DOI:
https://doi.org/10.51473/rcmos.v1i2.2025.1705Keywords:
cannabidiol – epilepsy – chronic pain – quality of life – treatmentAbstract
This integrative literature review aims to investigate the impacts of cannabidiol (CBD) on the quality of life of patients with refractory epilepsy and chronic pain, analyzing its effectiveness as an adjunctive or first-line therapy. The research is justified by the need to expand knowledge about the therapeutic potential of CBD, especially its ability to provide symptomatic relief and improve the quality of life of individuals with complex conditions such as refractory epilepsy and chronic pain. The investigation will be based on the legal framework regulating the medicinal use of CBD in Brazil, particularly Law No. 13.850/2019, which authorizes the medicinal use of cannabis and its derivatives, including CBD, for therapeutic purposes. General Objective: To describe the impacts of CBD on the quality of life of patients with epilepsy and chronic pain. Methodology: The study was conducted through an integrative literature review, using databases such as PubMed, BVS, and SciELO, with the descriptors "Cannabidiol - epilepsy - chronic pain." The inclusion criteria were publications between 2014 and 2024, selecting relevant articles and excluding duplicates and irrelevant topics. Expected Results: The aim is to obtain updated results demonstrating the efficacy of Cannabidiol in the treatment of epilepsy and chronic pain, contributing to expanding knowledge about the therapeutic potential of CBD and providing support for the development of more effective and targeted clinical guidelines.
Downloads
References
ANTUNES, F. J. R. Dor traumática musculoesquelética. Dolor: Investigación, Clínica & Terapéutica, v. 37, n. 3, p. 86-90, 2022.
AYDEDE, M.; SHRIVER, A. Recently introduced definition of “nociplastic pain” by the International Association for the Study of Pain needs better formulation. Pain, v. 159, n. 6, p. 1176-1177, 2018.
BARBOSA, D.; MACHADO, I. Uso medicinal da Cannabis. 2018. Disponível em: https://isabelaclaudio.jusbrasil.com.br/artigos/181415782/usomedicinal-da-cannabis
. Acesso em: 15 nov. 2024.
BEGHI, E. The epidemiology of epilepsy. Neuroepidemiology, v. 54, n. 2, p. 185-191, 2020.
BELOUSOVA, E. D. et al. New classifications of epilepsies and seizure types created by the International League against Epilepsy. Zhurnal Nevrologii i Psikhiatrii Imeni SS Korsakova, v. 117, n. 7, p. 99-106, 2017.
BIJLSMA, J. W. J.; KNAHR, K. Strategies for the prevention and management of osteoarthritis of the hip and knee. Best Practice & Research Clinical Rheumatology, v. 21, n. 1, p. 59-76, 2014.
BLAKE, D. R. et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology, v. 45, n. 1, p. 50-52, 2015.
BÔAS, G. K. V.; REZENDE, M. A. Discussão sobre o acesso aos medicamentos derivados da cannabis à luz da inovação em saúde no Brasil. Revista Fitos, v. 14, n. 2, p. 259-284, 2020.
BOLETI, A. P. A. et al. Aspectos bioquímicos e mecanismos terapêuticos do canabidiol na epilepsia. Neuroscience and Biobehavioral Reviews, v. 132, p. 1214-1228, 2022.
BRASIL. Lei nº 13.850, de 25 de junho de 2019. Dispõe sobre o uso medicinal da Cannabis e seus derivados, e dá outras providências. Diário Oficial da União, Brasília, 26 jun. 2019. Seção 1, p. 1-2.
BRASIL. Ministério da Saúde. Epilepsia: conheça a doença e os tratamentos disponíveis no SUS. 2022. Disponível em: https://www.gov.br/saude/pt-br/assuntos/noticias/2022/marco/epilepsia-conheca-a-doenca-e-os-tratamentos-disponiveis-no-sus
. Acesso em: 15 nov. 2024.
BRIGO, F.; IGWE, S. C.; LATTANZI, S. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews, n. 1, 2021.
BUTRICA, J. L. O uso medicinal da cannabis entre os gregos e romanos. Journal of Cannabis Therapeutics, v. 2, n. 2, p. 51-70, 2014.
CARVALHO, V. M.; DE BRITO, M. S.; GANDRA, M. Mães pela cannabis medicinal em um Brasil aterrorizado entre luzes e fantasmas. Fórum Sociológico, Série II, dez. 2017. Disponível em: https://journals.openedition.org/sociologico/1747
. Acesso em: 14 nov. 2024.
COIMBRA, B. Z. et al. Canabinóides como possível alternativa no tratamento de psoríase. Research, Society and Development, v. 11, n. 11, p. e450111134651, 2022.
DEVINSKY, O. et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, v. 55, n. 6, p. 791-802, 2014.
DOS REIS-NETO, E. T. et al. Prevalence of musculoskeletal symptoms in the five urban regions of Brazil—the Brazilian COPCORD study (BRAZCO). Clinical Rheumatology, v. 35, p. 1217-1223, 2016.
FISHER, R. S. et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia, v. 55, n. 4, p. 475-482, 2014.
FRIEDMAN, D.; DEVINSKY, O. Cannabinoids in the treatment of epilepsy. New England Journal of Medicine, v. 373, n. 11, p. 1048-1058, 2015.
GRAÇA, M. C. S. Canabinóides: estrutura química, efeitos farmacológicos e utilização terapêutica. 2020. Dissertação (Mestrado) — Egas Moniz School of Health & Science, Portugal.
GRAY, R. A.; WHALLEY, B. J. Os mecanismos de ação propostos do CBD na epilepsia. Epileptic Disorders, v. 22, p. 10-15, 2022.
GUYATT, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, v. 336, n. 7650, p. 924-926, 2014.
HAUSER, R. M.; LUBIN, F. D. A epigenética da epilepsia e sua progressão. Neuroscientist, v. 24, p. 186-200, 2018.
HEGMANN, K. Chronic Pain Guideline. American College of Occupational and Environmental Medicine, 2017. Disponível em: https://www.dir.ca.gov/dwc/MTUS/ACOEM-Guidelines/Chronic-PainGuideline.pdf
. Acesso em: 16 abr. 2024.
HOTTEN, W. et al. Assessment and Management of Chronic Pain. Institute for Clinical Systems Improvement, 2014. Disponível em: https://www.mnmed.org/application/files/3516/7173/5894/ChronicPain.pdf
. Acesso em: 14 nov. 2024.
IASP – International Association for the Study of Pain. Classification of Chronic Pain. IASP, 2017.
IASP. Taxonomia IASP. Disponível em: http://www.iasp-pain.org/Taxonomy
. Acesso em: 6 out. 2024.
LIGGIERI, A. et al. Tratado de dor musculoesquelética. São Paulo: Alef, 2019. p. 25-35.
LÖSCHER, W. et al. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacological Reviews, v. 72, n. 3, p. 606-638, 2020.
MARQUES, R. C. et al. Uso de canabidiol em tratamentos pediátricos. Anais do COMED, v. 7, p. 133-137, 2023.
MAZZEO, F.; MECCARIELLO, R.; GUATTEO, E. Molecular and epigenetic aspects of opioid receptors in drug addiction and pain management in sport. International Journal of Molecular Sciences, v. 24, n. 9, p. 7831, 2023.
OLIVEIRA, A. et al. Metassíntese: apontamentos para sistematização de revisões amplas e crítica interna à produção científica. CIAIQ, v. 1, 2015.
PERUCCA, P.; PERUCCA, E. Identifying mutations in epilepsy genes: impact on treatment selection. Epilepsy Research, v. 152, p. 18-30, 2019.
PESSOA, D. O. C.; LIRA, I. V.; SIQUEIRA, L. P. Cannabis sativa: uma revisão integrativa dos aspectos legais, toxicológicos e farmacoterapêuticos. Research, Society and Development, v. 10, n. 15, p. e18101522408, 2021.
PINHEIRO, B. S. et al. Importância da incorporação da Cannabis sativa L. no SUS. Revista Científica Eletrônica de Ciências Aplicadas da FAIT, n. 1, 2021. Disponível em: http://fait.revista.inf.br/imagens_arquivos/arquivos_destaque/8LmnPaDHrflMdZe_202.pdf
.
PROJETO DIRETRIZES AMB E CFM. Sociedade Brasileira de Reumatologia. Osteoartrite (Artrose): Tratamento. v. 8, 2014. Disponível em: http://www.projetodiretrizes.org.br/projeto_diretrizes/077.pdf
. Acesso em: 14 nov. 2024.
RAJA, S. N. et al. Definição revisada de dor pela Associação Internacional para o Estudo da Dor: conceitos, desafios e compromissos. IASP, 2020.
ROTHER, M.; CONAGHAN, P. G. A randomized, double-blind, phase III trial in moderate osteoarthritis knee pain comparing topical ketoprofen gel with ketoprofen-free gel. The Journal of Rheumatology, v. 40, n. 10, p. 1742-1748, 2014.
SCHEFFER, I. E. et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia, v. 58, n. 4, p. 512-521, 2017.
SILVA, P. N.; BARBOSA, M. L. C. Novas perspectivas para a terapia antiplaquetária: a evolução dos antagonistas do receptor P2Y12. Revista Virtual de Química, v. 13, n. 4, p. 999-1016, 2021.
YONESHIGUE, B. Cannabis medicinal: demanda no Brasil cresceu 9.311% desde autorização, mas enfrenta desafios no acesso e no preparo de médicos. O Globo, Rio de Janeiro, 04 fev. 2023. Disponível em: https://oglobo.globo.com/saude/medicina/noticia/2023/02/cannabis-medicinal-demanda-no-brasil-cresceu-9311percent-desde-autorizacao-mas-enfrenta-desafios-no-acesso-e-no-preparo-de-medicos.ghtml
.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2025 Isabela Rocha de Sousa , Nayane Barros Milhomem, Thales Guilherme Silva Campos (Autor)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This means you are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The use of this material is conditioned upon proper attribution to the original author(s), providing a link to the license, and indicating if changes were made. The license does not require permission from the author or the publisher as long as these conditions are met.
The Creative Commons license logo is displayed permanently in the footer of the journal.
The copyright of the manuscript can be retained by the authors without restrictions and can be requested at any time, even after publication in the journal.
